

UCLA

Health System

**Antimicrobial
Susceptibility
Summary
2024**

**Clinical Microbiology
Department of Pathology & Laboratory Medicine**

Antimicrobial Susceptibility Summary

**Clinical Microbiology
Department of Pathology and
Laboratory Medicine**

UCLA Health System

2024

The information contained in this booklet can also
be found at:

<https://asp.mednet.ucla.edu/pages/>

Select “Clinical Microbiology”
at the top of the homepage

Preface

This booklet contains up-to-date information to assist the clinician in making decisions concerning antimicrobial therapy and testing.

These tables summarize susceptibility data obtained for organisms isolated in the UCLA Clinical Microbiology Laboratory in 2023.

In order to provide the most meaningful information, the laboratory is selective in reporting antimicrobial susceptibility results.

Reporting guidelines are based on:

1. Identity of the organism
2. Body site of culture
3. Overall antibiogram of the organism
4. Therapeutically relevant antimicrobials
5. Formulary status of the antimicrobial

Non-formulary drugs are not routinely reported and controlled formulary agents are reported only in the appropriate setting: e.g. amikacin and tobramycin if resistant to gentamicin. Results of all relevant drugs tested, including those not reported, are available upon request.

We thank:

Daniel Uslan, MD, Chief Infection Prevention
Tara Vijayan, MD, Medical Director, Adult ASP
Ishminder Kaur, MD, Medical Director, Pediatric ASP
Kavitha Prabaker, MD, Hospital Epidemiologist SMH
Meganne Kanatani, PharmD, ID Pharmacist
Christine Pham, PharmD, ID Pharmacist
Ethan Smith, PharmD, ID Pharmacist
Lynn Chan, Pharm D, BCIDP ID Pharmacist
Allison Tsan, CLS, Sr. Specialist, Brentwood Annex
Stephanie Horiuchi, CLS, Sr. Specialist, Brentwood Annex

Guidelines for Interpretation of Minimal Inhibitory Concentrations (MICs)

MICs are interpreted as susceptible, susceptible dose dependent, intermediate, resistant, or non-susceptible according to Clinical and Laboratory Standards Institute (CLSI) M100, 34th edition guidelines. When deciding whether the interpretation is meaningful, one should consider the antimicrobial pharmacokinetics, taking into account dosage and route of administration, the infecting organism and site of infection, and previous clinical experience.

For antimicrobials without interpretive criteria consultation with Infectious Diseases strongly advised.

For additional information, please call the antimicrobial testing laboratory, or Antimicrobial Stewardship hotline.

Clinical Microbiology
UCLA Health System
Department of Pathology and Laboratory Medicine
171315

Frequently called numbers*:

Antimicrobial Stewardship: antimicrobialstewardship@mednet.ucla.edu
Antimicrobial Testing Laboratory: 310-794-2760
Drug Information Center: 310-267-8522
Infection Control SMH-UCLA: 424-259-4454
Infection Control RRUMC: 310-794-0187
Infectious Diseases Adult: 310-825-7225
Infectious Diseases Pediatric: 310-825-5235
RRMC and RNPH ID Pharmacist - Adult: 310-267-1423, page 71423
RRMC ID Pharmacist - Adult and Pediatric: 310-267-8510, page 92528
SMH ID Pharmacist - Adult: 310-267- 7567, page 91059
Microbiology Fellow on-call: page 90103

* If calling within UCLA system, dial the last 5 digits of the phone number.

Resources at UCLA through the Antimicrobial Stewardship Program (ASP)

The Antimicrobial Stewardship Program (ASP) has made resources available for the sole purpose of improving clinical outcomes of patients with infections. Questions and guidance on interpretation of culture reports (contaminant/pathogen), drug dosing, etc. are welcome. The ASP can be contacted numerous ways, depending on the urgency and clinical needs:

ASP Helpdesk/Consultation Email:

antimicrobialstewardship@mednet.ucla.edu

Website: <https://asp.mednet.ucla.edu/pages/>

Note that the website has a **guidebook**, with detailed information about specific clinical syndromes, interpretation of microbiology reports, and guidelines for treatment.

We encourage you to reach out to the program with questions. The program is staffed by:

- Christine Pham, PharmD, ID Pharmacist
- Ethan Smith, PharmD, ID Pharmacist
- Lynn Chan, PharmD, BCID, ID Pharmacist
- Meganne Kanatani, PharmD, ID Pharmacist
- Daniel Uslan, MD, Chief Infection Prevention
- Tara Vijayan, MD, Medical Director, Adult ASP
- Ishminder Kaur, MD, Medical Director, Pediatric ASP
- Kavitha Prabaker, MD, Hospital Epidemiologist SMH
- Bushra Rahman, MPH, Program Manager
- Omai Garner, PhD, Section Chief Clinical Microbiology
- Sukantha Chandrasekaran, PhD, D(ABMM), Associate Director, Clinical Microbiology

Table of Contents

Table	Page
--------------------	-------------

Adults

1	Adults (>21 y.o.) Most Common Gram-negative Bacteria – Non-Urine Isolates, % Susceptible.....	1
2	Adults (>21 y.o.) Gram-negative Bacteria – Non-Urine Isolates, % Susceptible.....	2
3	Adults (>21 y.o.) Gram-negative Bacteria – Urine Isolates, % Susceptible	3
4	Adults (>21 y.o.) Gram-positive Cocci, % Susceptible.....	4

Adults/Peds

5	Miscellaneous Gram-negative Bacteria	6
6	Multiple Drug Resistant Gram-negative Bacteria – All sources, % Susceptible.....	7

Peds

7	Pediatrics (\leq 21 y.o.) Gram-negative Bacteria – Non-Urine Isolates, % Susceptible.....	8
8	Pediatrics (\leq 21 y.o.) Gram-negative Bacteria – Urine Isolates, % Susceptible	9
9	Pediatrics (\leq 21 y.o.) Gram-positive Cocci, % Susceptible.....	10

Yeasts

10	Yeasts, %S, %I, %SDD, %R.....	12
----	-------------------------------	----

Emerging Resistance Concerns

11	Emerging Resistance Concerns.....	13
12	Resistance Trends	17
13	Carbapenem-resistant Enterobacterales (CRE)	20
14	Treatment Suggestions for Organisms for which Susceptibility Testing is Not Routinely Performed	22

Table of Contents

Table	Page
--------------------	-------------

Misc.

15	Blood: One Isolate per Patient	23
16	CSF: One Isolate per Patient	25
17	Mycobacteria, One Isolate per Patient per Source	26
18	Mycobacteria Antimicrobial Susceptibility Testing	27
19	California Mycobacterium tuberculosis % Resistant	28
20	Rapid Grower – Mycobacteria % Susceptible.....	29
21	CLSI Anaerobic Bacteria Cumulative Antibiogram, % Susceptible	30

Lab Info

22	Antimicrobials (IV, PO) Formulary Status and Cost Reference	31
23	Indications for Performing Routine Antimicrobial Susceptibility Tests – Aerobic Bacteria	34
24	Antimicrobial Agents Routinely Reported – Aerobic Bacteria	36
25	CLSI M62 – Expected Antimicrobial Susceptibility Patterns of the Most Commonly Isolated Nocardia Data Derived from CLSI M62	41
26	Susceptible MIC ($\mu\text{g/ml}$) Breakpoints for Aerobic Gram-negative Bacilli	42
27	Susceptible MIC ($\mu\text{g/ml}$) Breakpoints for Aerobic Gram-positive Cocci.....	43

Antimicrobial Stewardship Program

28	Antimicrobial Stewardship.....	44
----	--------------------------------	----

Glossary and Acronyms

—	Not routinely tested and/or not applicable
%R	Percent resistant
%S	Percent susceptible
Cipro R	Ciprofloxacin resistant
CP CRE	Carbapenemase producing carbapenem resistant Enterobacterales
CRE	Carbapenem Resistant Enterobacterales
CRPA	Carbapenem-Resistant Pseudomonas aeruginosa
I	Intermediate
ICU	Intensive care unit
IP	Inpatient (excludes intensive care unit and Emergency Department)
MDR	Multi-drug resistant
Mero R	Meropenem resistant
MIC	Minimal inhibitory concentration µg/mL
MRSA	Methicillin resistant Staphylococcus aureus
MSSA	Methicillin susceptible Staphylococcus aureus
Non-CP CRE	Non-Carbapenemase producing carbapenem resistant Enterobacterales
OP	Outpatient (includes Emergency Department collections)
Pip-Tazo R	Piperacillin tazobactam resistant
R	Resistant, can be resistant due to intrinsic resistance
S	Susceptible
SDD	Susceptible dose dependent
spp.	Species
UTIs	Urinary tract infections
V	Variable
VRE	Vancomycin-resistant Enterococcus

Table 1. Adults (> 21 y.o.) Most Common Gram-negative Bacteria – Non-Urine Isolates, % Susceptible

Organism	Location	No. Isolates	Penicillin				Cephalosporins				Carbapenems			Aminoglycosides			Fluoro-quinolone		Other
			Ampicillin	Amoxicillin-Clavulanic acid	Ampicillin - subactam	Piperacillin – tazobactam ¹	Cefazolin	Cefepime ¹	Ceftazidime	Ceftriaxone	Ertapenem	Imipenem	Meropenem	Amikacin	Gentamicin	Tobramycin	Ciprofloxacin	Levofloxacin	Trimethoprim - sulfamethoxazole
<i>Enterobacter cloacae</i> complex ²	OP	118	R	R	R	89	R	94	— ³	— ³	97	99	99	99	98	99	92	96	87
	IP	116	R	R	R	76	R	88	— ³	— ³	95	99	99	99	98	98	88	90	87
	ICU	56	R	R	R	64	R	86	— ³	— ³	88	99	99	99	96	96	93	93	93
<i>Escherichia coli</i>	OP	374	—	73	—	96	60	84	85	79	99	99	9	98	87	87	69	70	61
	IP	461	—	67	—	91	52	76	77	71	98	98	99	96	84	82	63	65	58
	ICU	147	—	58	—	82	34	65	66	59	99	99	99	95	82	80	48	52	51
<i>Klebsiella pneumoniae</i>	OP	182	R	88	—	91	76	85	86	85	98	99	99	98	92	91	83	91	81
	IP	246	R	80	—	83	65	76	78	76	94	97	96	97	89	84	73	85	72
	ICU	121	R	69	—	78	56	68	68	65	91	96	93	96	84	74	65	76	64
<i>Proteus mirabilis</i>	OP	131	—	91	—	99	13	92	97	85	99	— ⁴	99	93	92	89	73	73	73
	IP	137	—	85	—	98	9	87	96	80	99	— ⁴	99	88	84	80	61	62	60
	ICU	40	—	78	—	98	10	78	93	70	98	— ⁴	99	85	83	80	45	45	53
<i>Pseudomonas aeruginosa</i>	OP	526	R	R	R	89	R	91	90	R	R	88	92	— ⁵	— ⁵	93	81	77	R
	IP	439	R	R	R	80	R	86	84	R	R	81	85	— ⁵	— ⁵	95	77	71	R
	ICU	172	R	R	R	65	R	76	74	R	R	63	68	— ⁵	— ⁵	91	73	65	R

¹ %S includes %SDD

² *Enterobacter cloacae* complex includes *E. cloacae*, *E. asburiae*, and *E. hormaecheii*.

³ 3rd generation cephalosporins should not be used for serious infections.

⁴ *Proteus* spp. may have elevated imipenem MIC by mechanisms other than production of carbapenemases.

⁵ As of 2023, *Pseudomonas aeruginosa* breakpoints were revised, and tobramycin is now the only recommended aminoglycoside for systemic therapy. Amikacin is effective against *P. aeruginosa* only in urinary tract infections. Gentamicin is no longer recommended for *P. aeruginosa* infection at any site.

Table 2. Adults (> 21 y.o.) Gram-negative Bacteria – Non-Urine Isolates, % Susceptible

Organism	No. Isolates	Penicillin		Cephalosporins				Carbapenems			Aminoglycosides			Fluoro-quinolone		Other
		Amoxicillin-Clavulanic acid	Piperacillin-tazobactam	Cefazolin	Cefepime ¹	Ceftazidime	Ceftriaxone	Ertapenem	Imipenem	Meropenem	Amikacin	Gentamicin	Tobramycin	Ciprofloxacin	Levofloxacin	Trimethoprim sulfamethoxazole
<i>Citrobacter freundii</i> complex ²	57	R	79	R	95	— ³	— ³	98	98	98	98	89	91	88	89	80
<i>Klebsiella (Enterobacter) aerogenes</i>	149	R	85	R	97	— ³	— ³	97	94	99	99	99	99	96	97	96
<i>Enterobacter cloacae</i> complex ⁴	258	R	82	R	91	— ³	— ³	95	100	100	100	98	98	92	94	91
<i>Escherichia coli</i>	786	68	91	52	77	78	72	99	99	99	96	86	85	64	66	60
<i>Klebsiella oxytoca</i>	174	90	94	14	94	94	91	100	100	100	100	91	92	90	96	86
<i>Klebsiella pneumoniae</i>	453	80	85	66	77	78	76	95	97	97	97	89	85	75	85	73
<i>Morganella morganii</i>	84	R	99	R	98	— ³	— ³	99	— ⁵	100	92	83	93	70	71	73
<i>Proteus mirabilis</i>	242	88	98	9	90	97	84	100	— ⁵	100	90	88	86	69	69	67
<i>Serratia marcescens</i>	208	R	91	R	97	94	84	99	95	99	98	99	90	83	89	98
<i>Acinetobacter baumannii</i> complex ⁶	69	—	49	R	58	57	—	0	68	63	75	71	75	61	65	70
<i>Pseudomonas aeruginosa</i>	939	R	83	R	88	86	R	R	83	87	— ⁷	— ⁷	93	79	74	R
<i>Stenotrophomonas maltophilia</i>	111	R	R	R	—	—	R	R	R	R	R	R	R	—	51 ⁸	98 ⁸
<i>Achromobacter</i> spp.	76	—	95	R	12	75	—	—	83	84	12	9	11	8	38	93

¹ %S includes %SDD

² *Citrobacter freundii* complex includes *C. freundii*, *C. youngae*, *C. braakii*, and *C. werkmanii*.

³ 3rd generation cephalosporins should not be used for serious infections.

⁴ *Enterobacter cloacae* complex includes *E. cloacae*, *E. asburiae*, and *E. hormaechei*.

⁵ *Proteus* spp. and *Morganella* spp. may have elevated imipenem MIC by mechanisms other than production of carbapenemases.

⁶ *Acinetobacter baumannii* complex includes *A. baumannii*, *A. calcoaceticus*, *A. pittii*, and *A. nosocomialis*.

⁷ As of 2023, *Pseudomonas aeruginosa* breakpoints were revised, and tobramycin is now the only recommended aminoglycoside for systemic therapy. Amikacin is effective against *P. aeruginosa* only in urinary tract infections. Gentamicin is no longer recommended for *P. aeruginosa* infection at any site.

⁸ Levofloxacin and Trimethoprim sulfamethoxazole should not be used alone for antimicrobial therapy.

Table 3. Adults (> 21 y.o.) Gram-negative Bacteria – Urine Isolates, % Susceptible

Organism	Location	No. Isolates	Penicillin		Cephalosporin				Carbapenem			Aminoglycoside			Fluoro-quinolone		Other		
			Ampicillin	Amoxicillin – Clavulanic acid	Oral Cephalosporin ¹	Cefepime ²	Ceftazidime	Ceftriaxone	Ertapenem	Imipenem	Meropenem	Gentamicin	Tobramycin	Amikacin	Ciprofloxacin	Levofloxacin	Nitrofurantoin	Trimethoprim/ sulfamethoxazole	Piperacillin/ Tazobactam
<i>Enterobacter cloacae</i> complex	OP	223	R	R	R	92	— ³	— ³	95	99	99	96	96	—	92	90	48	85	77
	IP	25 ⁴	R	R	R	84	— ³	— ³	96	96	96	99	92	—	76	76	58	80	52
<i>Escherichia coli</i>	OP	9172	57	87	89	—	75	90	99	99	99	91	90	—	77	72	98	75	96
	IP	408	41	81	70	—	50	72	99	99	99	83	81	—	56	52	94	62	91
<i>Klebsiella pneumoniae</i>	OP	1571	R	R	89	—	44	90	99	99	99	95	94	—	86	84	29	86	90
	IP	144	R	R	64	—	0	66	94	97	97	83	77	—	63	58	20	65	68
<i>Proteus mirabilis</i>	OP	845	81	79	93	—	94	95	99	—	99	93	93	—	85	84	R	80	99
	IP	85	74	75	86	—	100	88	99	—	99	86	82	—	65	66	R	73	99
<i>Pseudomonas aeruginosa</i>	OP	433	R	R	R	95	93	R	R	87	93	— ⁵	97	99	84	81	R	R	92
	IP	108	R	R	R	92	87	R	R	83	89	— ⁵	97	99	80	73	R	R	82

¹ Oral cephalosporins include cefpodoxime and cephalexin for treatment of uncomplicated urinary tract infections.

² %S includes %SDD

³ 3rd generation cephalosporin should not be used for serious infections.

⁴ Calculated from fewer than the standard recommendation of 30 isolates.

⁵ As of 2023, *Pseudomonas aeruginosa* breakpoints were revised, and tobramycin is now the only recommended aminoglycoside for systemic therapy. Amikacin is effective against *P. aeruginosa* only in urinary tract infections. Gentamicin is no longer recommended for *P. aeruginosa* infection at any site.

Table 4. Adults (> 21 y.o.) Gram-positive Cocci, % Susceptible

Organism	Location	No. Isolates	Penicillins			Other										
			Ampicillin	Oxacillin	Penicillin	High Level Gentamicin ¹	Ciprofloxacin	Clindamycin	Daptomycin	Doxycycline	Erythromycin	Linezolid	Rifampin ²	Trimethoprim sulfamethoxazole	Vancomycin	Ceftaroline
<i>Staphylococcus aureus</i>	All	2399	—	75 ³	25	—	74	72	100	98	55	100	99	96	100	100
Oxacillin-resistant <i>S. aureus</i> (MRSA)	OP	416	—	R ³	R ³	—	28	65	100	97	16	100	99	91	100	99
	IP	148	—	R ³	R ³	—	20	55	100	100	19	100	99	91	100	99
	ICU	75	—	R ³	R ³	—	15	44	100	97	17	100	97	95	100	100
Oxacillin-susceptible <i>S. aureus</i> (MSSA)	OP	1271	—	100	35	—	90	75	100	98	67	100	100	97	100	100
	IP	279	—	100	30	—	90	74	100	98	67	100	100	96	100	99
	ICU	156	—	100	22	—	91	69	100	99	65	100	98	99	100	100
<i>Staphylococcus epidermidis</i>	All	522	—	47	13	—	63	63	100	88	38	100	98	67	100	—
<i>Staphylococcus haemolyticus</i>	All	62	—	52	40	—	55	57	100	88	37	100	86	68	100	—
<i>Staphylococcus lugdunensis</i> ⁴	All	329	—	88	45	—	99	81	100	99	79	100	100	100	100	—
<i>Staphylococcus pseudintermedius/ intermedius</i>	All	62	—	61	16	—	60	55	100	55	45	100	97	55	100	—
Coagulase negative <i>Staphylococcus</i> ^{5,6}	All	103	—	64	32	—	69	67	99	98	40	100	97	81	100	—
<i>Enterococcus</i> spp. ^{7 8}	All	46	74	—	—	— ⁹	61	R	84	69	42	100	31	R	78	R
<i>Enterococcus faecalis</i> ⁷	All	622	100	—	—	72 ¹⁰	69	R	97	41	R	100	19	R	98	R
<i>Enterococcus faecium</i> ⁷	All	260	15	—	—	92 ¹⁰	10	R	90 ¹¹	54	R	100	5	R	34	R

¹ High level gentamicin 500µg/mL.

² Rifampin should not be used as monotherapy.

³ *Staphylococcus* resistant to oxacillin are resistant to all other beta lactams except ceftaroline.

⁴ *S. lugdunensis* is best treated with a Beta-lactam agent.

⁵ *S. saprophyticus* urinary tract infections respond to antibiotic concentrations achieved in urine with agents commonly used to treat acute uncomplicated UTIs.

⁶ Excluding *S. epidermidis*, *S. lugdunensis* and *S. pseudintermedius*.

⁷ Serious Enterococcal infections need combination therapy of ampicillin plus ceftriaxone or an aminoglycoside.

⁸ *Enterococcus* spp. excludes *E. faecalis* and *E. faecium*.

⁹ Insufficient data to calculate % susceptible.

¹⁰ % susceptible calculated with isolates tested from sterile body sites. *E. faecalis* n=71 and *E. faecium* n=89.

¹¹ % susceptible includes susceptible dose dependent.

Table 4. Adults (> 21 y.o.) Gram-positive Cocci, % Susceptible (cont.)

Organism	No. Isolates	Penicillins		Cephalosporins		Clindamycin	Other					
		Amoxicillin	Penicillin	Cefotaxime	Ceftriaxone		Doxycycline	Erythromycin	Levofloxacin	Trimethoprim – sulfamethoxazole	Tetracycline	Vancomycin
<i>Streptococcus pneumoniae</i>	45	93	—	—	—	80	80	62	98	69	—	100
Meningitis ¹		—	62	89	84	—	—	—	—	—	—	—
Non-meningitis ²		—	93	96	96	—	—	—	—	—	—	—
Viridans group <i>Streptococcus spp.</i> ³	104	—	66 ⁴	95	94	—	—	—	—	—	—	100
<i>Streptococcus anginosus group</i>	80	—	98	99	99	—	—	—	—	—	—	100
<i>Streptococcus agalactiae</i> (Group B streptococci)	80	—	100	—	—	49	—	—	—	—	—	100
<i>Streptococcus pyogenes</i> (Group A streptococci)	32	—	100	—	—	75	—	71	—	—	63	100

¹ % susceptible for penicillin, cefotaxime and ceftriaxone applies to patients with meningitis.

² % susceptible for penicillin, cefotaxime and ceftriaxone applies to patients without meningitis.

³ Excluding *Streptococcus anginosus group*.

⁴ 29% Intermediate (MIC 0.25-2 µg/ml).

Table 5. Miscellaneous Gram-negative Bacteria

Organism	No. Isolates	% beta-lactamase positive ¹
<i>Haemophilus influenzae</i>	183 (pts. >21 y.o) 37 (pts. ≤21 y.o.)	34 27
<i>Moraxella catarrhalis</i>	46 (pts. >21 y.o) 11 (pts. ≤21 y.o.)	96 100
<i>Neisseria gonorrhoeae</i>	<p>The current therapy recommendation is ceftriaxone. Culture and susceptibility testing should be performed in cases of treatment failure. See https://www.cdc.gov/gonorrhea/about/index.html</p> <p>PER STD 2021 treatment guidelines, the recommended treatment for gonorrhea is ceftriaxone 500 mg IM x 1 for patients <150 kg, 1g for patients ≥ 150 kg.</p> <p>Doxycycline 100mg twice daily for 7 days is recommended if there is suspicion or confirmed Chlamydia co-infection</p>	
<i>Neisseria meningitidis</i>	<p>The current therapy recommendation is ceftriaxone for treating meningococcal infections. Penicillin may be considered after susceptibilities return and MIC is ≤0.12 µg/mL (Antimicrob Agents Chemother 56:2268, 2012). Reports have noted some isolates with resistance to fluoroquinolones, agents often used for prophylaxis (MMWR. 2008. 57:173-175).</p> <p>Sanford guide 2022 Recommended: Ceftriaxone Alternative: Meropenem</p>	

¹ Resistant to ampicillin, amoxicillin, and penicillin.

**Table 6. Multiple Drug Resistant Gram-negative Bacteria – All sources
% Susceptible**

Organism	Amikacin		Aztreonam		Ceftazidime-Avibactam ¹		Ceftolozane-Tazobactam ¹		Tigecycline ²		Meropenem-Vaborbactam ¹		Eravacycline ^{2,3}		Omadacycline ^{2,4}	
	Number of isolates tested	% Susceptible	Number of isolates tested	% Susceptible	Number of isolates tested	% Susceptible	Number of isolates tested	% Susceptible	Number of isolates tested	% Susceptible	Number of isolates tested	% Susceptible	Number of isolates tested	% Susceptible	Number of isolates tested	% Susceptible
Carbapenem Resistant Enterobacteriales (CRE)⁵	324	84	81	12	324	95	320	73	85	92	81	85	81	75	81	82

Organism	Number of Isolates	Amikacin	Gentamicin	Ciprofloxacin	Piperacillin-Tazobactam	Cefepime	Ceftazidime	Ceftazidime-Avibactam ^{1,2}	Ceftolozane-Tazobactam ^{1,2}	Minocycline	Trimethoprim-sulfamethoxazole
<i>Pseudomonas aeruginosa</i>, Imipenem or Meropenem resistant	202	89 ⁶	—	49	46	59	55	86	87	0	R
<i>Pseudomonas aeruginosa</i>, Imipenem and Meropenem resistant	140	88 ⁶	—	44	28	45	40	78	83	0	R
<i>Acinetobacter baumannii</i> complex⁷, Meropenem resistant	27 ⁸	26	19	11	0	4	7	—	—	55	26

¹ Restricted formulary. ID consult required.

² Interpretations are based on FDA breakpoints. There are no current CLSI breakpoints available for these drugs. Please refer to the FDA website at: <https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria>.

³ FDA guidelines indicated that clinical efficacy was shown for *Citrobacter freundii*, *Enterobacter cloacae*, *Escherichia coli*, *Klebsiella oxytoca* & *Klebsiella pneumonia*.

⁴ FDA breakpoint for Omadacycline applies to *Klebsiella pneumoniae* only and indicated for Community Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin/Skin Structure Infections (ABSSI).

⁵ CRE: Enterobacteriales resistant to one or more carbapenem i.e. Ertapenem, Imipenem or Meropenem

⁶ Amikacin for *Pseudomonas aeruginosa* is for Urine isolates only.

⁷ *Acinetobacter baumannii* complex includes *A. baumannii*, *A. calcoaceticus*, *A. pittii* and *A. nosocomialis*.

⁸ Calculated from fewer than the standard recommendation of 30 isolates.

Table 7. Pediatrics (≤ 21 y.o.) Gram-negative Bacteria – Non-Urine Isolates, % Susceptible

Organism	No. Isolates	Penicillins				Cephalosporins				Carbapenems			Aminoglycosides			Fluoroquinolone	Other
		Ampicillin ¹	Amoxicillin-Clavulanic acid	Ampicillin-sulbactam ¹	Piperacillin-tazobactam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone ²	Ertapenem	Imipenem	Meropenem	Amikacin	Gentamicin	Tobramycin	Ciprofloxacin ³	Trimethoprim – sulfamethoxazole
<i>Enterobacter cloacae</i> complex ⁴	31	R	R	R	94	R	100	— ⁵	— ⁵	100	100	100	100	100	100	100	94
<i>Escherichia coli</i>	59	—	75	—	97	61	83	85	75	100	100	100	95	90	90	80	70
<i>Klebsiella pneumoniae</i>	47	R	83	—	87	68	85	85	83	100	100	100	100	92	92	87	77
<i>Serratia marcescens</i>	24 ⁶	R	R	R	92	R	96	— ⁵	— ⁵	100	96	100	92	92	75	79	96
<i>Pseudomonas aeruginosa</i>	75	R	R	R	91	R	91	92	R	R	84	91	— ⁷	— ⁷	97	91	R

¹ Ampicillin and Ampicillin-sulbactam testing were discontinued on July 26, 2016.

² Ceftriaxone and cefotaxime have comparable activity against *Enterobacteriaceae*.

³ Ciprofloxacin is associated with arthropathy and histological changes in weight-bearing joints of juvenile animals and should only be used when no safe and effective alternatives exist.

⁴ *Enterobacter cloacae* complex includes *E. cloacae*, *E. asburiae*, and *E. hormaecheii*.

⁵ 3rd generation cephalosporins should not be used for serious infections.

⁶ Calculated from fewer than the standard recommendation of 30 isolates

⁷ As of 2023, *Pseudomonas aeruginosa* breakpoints were revised, and tobramycin is now the only recommended aminoglycoside for systemic therapy. Amikacin is effective against *P. aeruginosa* only in urinary tract infections. Gentamicin is no longer recommended for *P. aeruginosa* infection at any site.

Table 8. Pediatrics (≤ 21 y.o.) Gram-negative Bacteria – Urine Isolates, % Susceptible

Organism	No. Isolates	Penicillins		Cephalosporins			Carbapenems			Amino-glycosides			Fluoroqui-nolone	Other		
		Ampicillin	Amoxicillin - Clavulanic acid	Oral Cephalosporins ¹	Cefepime	Ceftazidime	Ceftriaxone	Ertapenem	Imipenem	Meropenem	Amikacin	Gentamicin	Tobramycin	Ciprofloxacin ²	Trimethoprim – sulfamethoxazole	Nitrofurantoin
<i>Enterobacter cloacae</i> complex ³	14 ⁴	R	R	R	86	—	—	93	100	100	—	100	—	100	93	50
<i>Klebsiella (Enterobacter) aerogenes</i>	17 ⁴	R	R	R	88	—	—	100	100	100	—	94	—	82	88	12
<i>Escherichia coli</i>	882	58	86	91	—	—	92	100	99	99	—	91	91	85	76	99
<i>Klebsiella pneumoniae</i>	91	R	95	91	—	—	92	100	99	99	—	98	95	84	86	23
<i>Proteus mirabilis</i>	85	84	84	96	—	—	98	100	— ⁵	99	—	95	97	93	85	R
<i>Pseudomonas aeruginosa</i>	26 ⁴	R	R	R	89	89	R	R	92	92	100	— ⁶	100	96	R	R

¹ Oral Cephalosporins include Cefpodoxime and Cephalexin for treatment of uncomplicated urinary tract infections.

² Ciprofloxacin is associated with arthropathy and histological changes in weight-bearing joints of juvenile animals and should only be used when no safe and effective alternatives exist.

³ *Enterobacter cloacae* complex includes *E. cloacae*, *E. asburiae*, and *E. hormaecheii*.

⁴ Calculated from fewer than the standard recommendation of 30 isolates.

⁵ *Proteus* spp. may have elevated imipenem MIC by mechanisms other than production of carbapenemases.

⁶ As of 2023, *Pseudomonas aeruginosa* breakpoints were revised, and tobramycin is now the only recommended aminoglycoside for systemic therapy. Amikacin is effective against *P. aeruginosa* only in urinary tract infections. Gentamicin is no longer recommended for *P. aeruginosa* infection at any site.

Table 9. Pediatrics (≤ 21 y.o.) Gram-positive Cocci, % Susceptible

Organism	Location	No. Isolates	Penicillins			Cephalosporins		Others										
			Ampicillin	Oxacillin	Penicillin	Ceftriaxone	Cefotaxime	High Level Gentamicin ¹	Ciprofloxacin ²	Clindamycin	Daptomycin	Doxycycline	Erythromycin	Linezolid	Rifampin ³	Trimethoprim-sulfamethoxazole	Vancomycin	Ceftaroline
<i>Staphylococcus aureus</i> (All)	OP	345	—	90	27	—	—	—	87	80	99	99	64	99	99	96	99	99
	IP	146	—	85	34	—	—	—	88	77	99	99	64	99	99	97	99	99
Oxacillin-resistant <i>S. aureus</i> (MRSA) ³	OP	36	—	R ⁴	R ⁴	R ⁴	R ⁴	—	31	75	99	99	19	99	99	92	99	99
	IP	22 ⁵	—	R ⁴	R ⁴	R ⁴	R ⁴	—	55	59	99	99	27	99	99	91	99	99
Oxacillin-susceptible <i>S. aureus</i> (MSSA)	OP	315	—	99	30	—	—	—	93	80	99	99	69	99	99	96	99	99
	IP	126	—	99	40	—	—	—	93	80	99	99	71	99	99	98	99	99
Coagulase negative <i>Staphylococcus</i> ⁶	OP	19 ⁵	—	68	33	—	—	—	90	61	95	99	39	99	99	95	99	—
	IP	24 ⁵	—	57	25	—	—	—	83	75	99	95	38	99	96	79	99	—
<i>Staphylococcus epidermidis</i>	All	73	—	37	10	—	—	—	75	52	99	91	27	99	99	66	99	—
<i>Staphylococcus lugdunensis</i>	All	24 ⁵	—	96	50	—	—	—	99	88	99	99	92	99	99	99	99	—
<i>Enterococcus</i> spp. ⁷	All ⁸	3 ⁵	99	—	—	R	R	67	99	R	100	67	R	99	67	R	99	—
<i>Enterococcus faecalis</i>	All	59	99	—	—	R	R	80	70	R	95	42	R	99	17	R	99	—
<i>Enterococcus faecium</i>	All	5 ⁵	0	—	—	R	R	100	40	R	89 ⁹	80	R	99	20	R	80	—

¹ High level Gentamicin 500 µg/ml.

² Ciprofloxacin is associated with arthropathy and histological changes in weight bearing joints of juvenile animals and should only be used when no safe and effective alternatives exist.

³ Rifampin should not be used as monotherapy.

⁴ *Staphylococcus* resistant to oxacillin are resistant to cefazolin, cephalixin, ceftriaxone and all other beta-lactams except ceftaroline.

⁵ Calculated from fewer than the standard recommendation of 30 isolates.

⁶ Excludes *S. epidermidis* and *S. lugdunensis*.

⁷ Excludes *E. faecalis* and *E. faecium*.

⁸ Includes isolates tested from all body sites.

⁹ %SDD

Table 9. Pediatrics (≤ 21 y.o.) Gram-positive Cocci, % Susceptible (cont.)

Organism	No. Isolates	Penicillins		Cephalosporins		Other				
		Amoxicillin	Penicillin	Cefotaxime	Ceftriaxone	Clindamycin	Doxycycline	Erythromycin	Trimethoprim – sulfamethoxazole	Vancomycin
<i>Viridans group Streptococcus</i>	21 ¹	—	67	91	86	—	—	—	—	100
<i>Streptococcus anginosus</i>	9 ¹	—	99	99	99	—	—	—	—	100
<i>Streptococcus pneumoniae</i>	9 ¹	89	—	—	—	100	100	100	50	100
Meningitis ²		—	89	89	89	—	—	—	—	—
Non-meningitis ³		—	99	99	99	—	—	—	—	—

¹ Calculated from fewer than the standard recommendation of 30 isolates.

² % susceptible for penicillin, cefotaxime and ceftriaxone applies to patients with meningitis.

³ % susceptible for penicillin, cefotaxime and ceftriaxone applies to patients without meningitis.

Table 10. Yeasts, %S, %I, %SDD, %R, 2022-2023

1. Most yeast infections can be treated empirically. Antifungal testing of yeasts may be warranted for the following:
 - Oropharyngeal or vaginal infections due to *Candida* spp. in patients who appear to be failing therapy.
 - Management of invasive *Candida* spp. infections when utility of an azole agent is uncertain (e.g., *Candida* spp. other than *C. albicans*), per IDSA guidelines for candidiasis: CID 2016:62, E1-E50. Clinical Practice Guidelines for the Management of Candidiasis.
2. Isolation of *Candida* in respiratory specimens of immunocompetent patients should be interpreted as airway colonization.

Organism	No. of Isolates	Percent Susceptible, Susceptible Dose Dependent, Intermediate, Resistant at Breakpoints ^{1, 2}															
		MIC µg/mL	Fluconazole ³			Voriconazole ³			Caspofungin ³			Micafungin ³			Anidulafungin ³		
			S	SDD	R	S	I	R	S	I	R	S	I	R	S	I	R
<i>Candida albicans</i>	333	MIC µg/mL	≤ 2	4	≥ 8	≤ 0.12	0.25-0.5	≥ 1	≤ 0.25	0.5	≥ 1	≤ 0.25	0.5	≥ 1	≤ 0.25	0.5	≥ 1
		%	90	6	5	88	10	2	99	0	0	99	0	0	99	0	0
<i>Candida glabrata</i>	179	MIC µg/mL	—	≤ 32	≥ 64	— ⁴	— ⁴	— ⁴	≤ 0.12	0.25	≥ 0.5	≤ 0.06	0.12	≥ 0.25	≤ 0.12	0.25	≥ 0.5
		%	—	84	16	— ⁴	— ⁴	— ⁴	88	10	2	99	0	1	98	1	2
<i>Candida parapsilosis</i>	75	MIC µg/mL	≤ 2	4	≥ 8	≤ 0.12	0.25-0.5	≥ 1	≤ 2	4	≥ 8	≤ 2	4	≥ 8	≤ 2	4	≥ 8
		%	85	4	11	89	3	8	99	0	0	99	0	0	92	8	0
<i>Candida tropicalis</i>	50	MIC µg/mL	≤ 2	4	≥ 8	≤ 0.12	0.25-0.5	≥ 1	≤ 0.25	0.5	≥ 1	≤ 0.25	0.5	≥ 1	≤ 0.25	0.5	≥ 1
		%	88	4	8	90	4	6	98	0	2	99	0	0	98	2	0
<i>Candida krusei</i>	31	MIC µg/mL	—	—	—	≤ 0.5	1	≥ 2	≤ 0.25	0.5	≥ 1	≤ 0.25	0.5	≥ 1	≤ 0.25	0.5	≥ 1
		%	R	R	R	97	3	0	94	3	3	94	0	6	97	0	3
<i>Candida guilliermondii</i>	9 ⁵	MIC µg/mL	—	—	—	—	—	—	≤ 2	4	≥ 8	≤ 2	4	≥ 8	≤ 2	4	≥ 8
		%	—	—	—	—	—	—	99	0	0	99	0	0	99	0	0

¹ CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast. 4th ed. CLSI Standard M27. Wayne, PA.: Clinical and Laboratory Standards Institute; 2017

² CLSI. Performance Standards for Antifungal Susceptibility Testing of Yeasts. 2nd ed. CLSI Standard M27. Wayne, PA.: Clinical and Laboratory Standards Institute; 2017

³ Not all isolates were tested against all four antifungal agents.

⁴ For *C. glabrata* and voriconazole, current data are insufficient to demonstrate correlation between *in vitro* susceptibility testing and clinical outcome.

⁵ Calculated from fewer than the standard recommendation of 30 isolates.

Table 11. Emerging Resistance Concerns

When unusual antimicrobial resistance (R) is observed, an Infectious Disease (ID) consult is strongly suggested to optimize therapy and prevent nosocomial transmission.

Organism	Resistant to:	Percent Resistant:	Therapeutic Options	Comments
<i>Staphylococcus aureus</i>	Oxacillin (MRSA)	Adults (>21 y.o.) Inpatients (n=1012) ¹ 36% Outpatients (n=1423) ¹ 18% Pediatrics (≤21 y.o.) Inpatients (n=146) ¹ 15% Outpatients (n=317) ¹ 10%	vancomycin ceftaroline daptomycin	MRSA are clinically resistant to all β-lactams, β-lactam / β-lactamase inhibitor combinations and carbapenems, excluding ceftaroline. ¹ MRSA are also typically resistant to fluoroquinolones
<i>Streptococcus pneumoniae</i> (non-meningitis)	Penicillin (MIC > 2 μg/ml)	All isolates (n=53) Penicillin MIC >2 μg/ml 2%	ceftriaxone or cefotaxime or vancomycin	If susceptible (MIC ≤2.0 μg/ml), high dose penicillin has been shown to be effective for infections other than meningitis. ²
<i>Streptococcus pneumoniae</i> (non-meningitis)	Cefotaxime, Ceftriaxone (Penicillin resistant always)	All isolates (n=53) Cefotaxime and ceftriaxone Low level R (n=1) 2% High level R (n=1) 2%	vancomycin levofloxacin	If low-level resistance (MIC=2.0 μg/ml), high dose cefotaxime or ceftriaxone may be effective for infections other than meningitis. ²

¹ Isolates from all sources.

² The Sanford Guide to Antimicrobial Therapy. (2020). Sperryville, VA: Antimicrobial Therapy, Inc.

Table 11. Emerging Resistance Concerns
(cont.)

When unusual antimicrobial resistance (R) is observed, an Infectious Disease (ID) consult is strongly suggested to optimize therapy and prevent nosocomial transmission.

Organism	Resistant to:	Percent Resistant:	Therapeutic Options	Comments
Viridans group <i>Streptococcus</i> (excludes <i>S. anginosus</i> group ¹)	penicillin	Blood isolates (n = 57) low level R (n=15) 26% high level R (n=1) 2%	vancomycin or penicillin + aminoglycoside	Level of penicillin resistance is particularly useful in guiding therapy for endocarditis. ² For low level resistance, MICs are 0.25–2.0 µg/ml; for high level, MICs are >2.0 µg/ml. ³
<i>Enterococcus</i> spp.	vancomycin (VRE)	Blood isolates <i>E. faecium</i> (n = 90) 66% <i>E. faecalis</i> (n = 82) 2%	Check in vitro susceptibility results and contact Infectious Diseases.	Vancomycin-resistant <i>Enterococcus</i> (VRE) are often resistant to many potentially useful agents. Therapeutic management must be determined on a case-by- case basis.
	High level gentamicin 500 µg/mL	Blood isolates <i>E. faecium</i> (n = 90) 8% <i>E. faecalis</i> (n = 82) 26%	Check in vitro susceptibility results and contact Infectious Diseases.	Both aminoglycoside and cell wall active agent (ampicillin, penicillin, or vancomycin) must be susceptible for synergistic interaction.

¹ *Streptococcus anginosus*, *Streptococcus intermedius*, and *Streptococcus constellatus*

² The Sanford Guide to Antimicrobial Therapy. (2020). Sperryville, VA: Antimicrobial Therapy, Inc.

³ Baddour, L. M., et al. (2015). Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. *Circulation*, 132(15), 1435–1486.

Table 11. Emerging Resistance Concerns (cont.)

Organism	Resistant to:	Percent Resistant:	Therapeutic Options	Comments
<i>Klebsiella</i> spp. (not aerogenes) <i>E. coli</i>	ceftriaxone or other 3rd generation cephalosporin	Blood isolates: <i>Klebsiella</i> spp.(n = 190) 25% <i>E. coli</i> (n = 333) 32%	ertapenem ciprofloxacin	In vitro resistance to 3rd generation cephalosporins suggests the strain is producing extended-spectrum β -lactamases (ESBL), or AmpC
<i>K. pneumoniae</i> and other <i>Enterobacterales</i>	carbapenem	All isolates (n = 18395): 3% Blood isolates (n=682): 2%	Check in vitro susceptibility results and contact Infectious Diseases.	Decreased susceptibility to carbapenems is increasing primarily among ICU patients' isolates. These isolates may be resistant to all available antimicrobial agents.
<i>Citrobacter freundii</i> complex <i>Enterobacter cloacae</i> complex <i>Klebsiella</i> (<i>Enterobacter</i>) <i>aerogenes</i>	3rd generation cephalosporins (e.g. ceftriaxone)	See comments	cefepime aminoglycoside ciprofloxacin ertapenem meropenem trimeth-sulfa	Organisms listed typically produce inducible β -lactamases. Isolates that appear susceptible to 3rd generation cephalosporins may develop resistance during therapy. ¹
<i>Pseudomonas aeruginosa</i>	cefepime and/or piperacillin-tazobactam	All isolates: (n=1568) 15%	Check in vitro susceptibility results and contact Infectious Diseases.	Therapeutic management must be determined on a case by case basis.
<i>Acinetobacter baumannii</i> complex	amikacin, cefepime, ceftazidime, ciprofloxacin, meropenem, piperacillin-tazobactam, and trimeth-sulfa	All isolates: (n=109) 16%	Check in vitro susceptibility results and contact Infectious Diseases.	Therapeutic management must be determined on a case by case basis.

¹ Tamma P, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. IDSA Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections. IDSA 2024. Version 4.0

Table 11. Emerging Resistance Concerns (cont.)

When specific antimicrobial resistance (R) is detected, an Infectious Disease (ID) consult is strongly suggested.

Organism	If Resistant to:	Therapeutic Options	Comments
<i>Candida krusei</i>	micafungin	voriconazole ¹ amphotericin ²	Typically susceptible to micafungin. Breakthrough infections have been reported. ³
	voriconazole	micafungin ⁴ amphotericin ^{2, 5}	Intrinsically resistant to fluconazole ^{6, 7} Typically susceptible to voriconazole ^{6, 7}
<i>Candida glabrata</i>	micafungin	fluconazole ⁸ voriconazole ¹ amphotericin ^{2, 5}	echinocandin resistance may be emerging. ⁶
	fluconazole	voriconazole ¹ micafungin ⁴ amphotericin ^{2, 5}	Typically resistant to fluconazole. ^{6, 7}
<i>Candida albicans</i>	micafungin	fluconazole ⁸ amphotericin ^{2, 5}	Typically susceptible to micafungin. ^{6, 7}
	fluconazole	micafungin ⁴ amphotericin ^{2, 5}	Typically susceptible to fluconazole but resistance can develop during therapy. ^{6, 7}
<i>Candida auris</i>	Often resistant to azoles, amphotericin and some are echinocandin resistant	Infectious Disease consult is strongly suggested	<i>Candida auris</i> is an emerging multi-drug resistant organism, able to cause wide range of infections.

For additional resistance data, see Tables 5-13.

These are therapeutic options in adults. For therapeutic options in pediatric patients, please contact the Antimicrobial Stewardship.

¹ Voriconazole has poor penetration in urine.

² Liposomal amphotericin has poor penetration in urine.

³ Tavernier, E., et al. Development of echinocandin resistance in *Candida krusei* isolates following exposure to micafungin and caspofungin in a BM transplant unit. *Bone Marrow Transplant* 50, 158–160 (2015)

⁴ micafungin may not reach therapeutic concentration in the CSF, vitreous fluid or urine.


⁵ Among patients without baseline renal dysfunction and suspected azole- and echinocandin-resistant *Candida* infections, liposomal amphotericin B is recommended. Infectious Disease consult is highly recommended.

⁶ Pappas, P. G., et al. (2016). Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 62(4), e1–e50.

⁷ Treatment Guidelines from the Med. Letter-Antifungal Drugs. 2012;10(120):61-68

⁸ For initial treatment with fluconazole, careful consideration should be given, especially in critically ill patients or those with prior azole exposure or prophylaxis. Infectious Disease consult is highly recommended.

Table 12. Resistance Trends: 1990-2023




NOTE:

2013-2015: Derived from RRH data

2016-2023: Combined data from RRH and SMH

Table 12. Resistance Trends: 1990-2022
(cont.)




NOTE:

Resistance data trend from all sources

2012-2015: Derived from RRH data

2016-2022: Combined data from RRH and SMH

Table 12. Resistance Trends: 1990-2022
(cont.)



Note: No data prior to 1998
 2012-2015: Derived from RRH data
 2016-2022: Combined data from RRH and SMH

Table 13. Carbapenem-resistant Enterobacterales (CRE), 2018-2023

Year	Non-CP CRE	KPC	OXA	NDM	NDM & OXA	KPC & OXA	VIM	IMP
2018	31	24	4	3	1	0	0	0
2019	25	32	0	2	1	0	0	0
2020	42	25	2	5	1	1	0	0
2021	67	25	2	5	0	1	0	0
2022	104	15	3	5	1	0	0	0
2023	57	23	6	7	1	1	0	0




Table 13. Carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), 2023 (Cont.)

Year	Non-CP CRPA	KPC	OXA	NDM	VIM	IMP	NDM & OXA	KPC & OXA
2023	114	0	2	5	0	0	0	0




Table 14. Treatment Suggestions for Organisms for which Susceptibility Testing is not Routinely Performed

Organism	Recommended	Alternate treatment	Comments / Also Effective
<i>Aerococcus urinae</i>	Amoxicillin	Levofloxacin or Ciprofloxacin	Fluoroquinolones resistant strains (27%-33%) have been reported. ¹
<i>Bordetella pertussis</i> ²	Azithromycin or Clarithromycin	Trimethoprim-sulfamethoxazole	
<i>Campylobacter jejuni</i> ²	Azithromycin	Consult with ID	Trimethoprim-sulfamethoxazole, Penicillin & Cephalosporins NOT Active
<i>Campylobacter fetus</i> ²	Gentamicin	Imipenem or Ceftriaxone	Ampicillin
<i>Legionella spp.</i> ²	Levofloxacin or Azithromycin	Moxifloxacin or doxycycline	
<i>Mycoplasma pneumoniae</i> ²	Doxycycline	Azithromycin, Minocycline	Clindamycin & B-lactams NOT Effective . Increasing macrolide resistance.
<i>Mycoplasma hominis</i>	Consult with ID	Consult with ID	Resistant to Erythromycin and azithromycin. Fluoroquinolone and Tetracycline resistant strains have been reported. ³
<i>Stenotrophomonas maltophilia</i> ⁴	Consult with ID	Consult with ID	Fluoroquinolone ⁵ For moderate to severe infections, combination therapy should be considered until clinical improvement occurs.
<i>Streptococcus agalactiae</i> (Group B Streptococcus)	Penicillin, Ampicillin, or Amoxicillin	Cefazolin or Vancomycin	
<i>Cutibacterium (Propionibacterium) acnes</i> ²	Penicillin, Ceftriaxone	Vancomycin, Daptomycin, Linezolid	Resistant to Metronidazole
<i>Ureaplasma</i>	Azithromycin, Doxycycline		Resistant to Clindamycin. Tetracycline resistant strains have been reported. ³

¹ Berteau, T., Roy, F. É., Bestman-Smith, J., Lapierre, S. G., Longtin, J., Dufresne, S. F., ... & Leduc, J. M. (2018, November). 2001. Susceptibility of *Aerococcus urinae* to Fluoroquinolones: Broth Microdilution and Gradient Diffusion. In *Open Forum Infectious Diseases* (Vol. 5, No. suppl_1, pp. S582-S583). US: Oxford University Press.


² The Sanford Guide to Antimicrobial Therapy. (2020). Sperryville, VA: Antimicrobial Therapy, Inc.

³ Waites, K. B., Katz, B., & Schelonka, R. L. (2005). *Mycoplasmas and Ureaplasma as neonatal pathogens*. *Clinical microbiology reviews*, 18(4), 757–789.

⁴ Susceptibility performed on *Stenotrophomonas maltophilia* isolates from sterile body sites and Cystic Fibrosis cases.

⁵ Tamma P, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. IDSA Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections. IDSA 2024. Version 4.0

Table 15. Blood: One Isolate per Patient, 2023



Most Common Organism	n	% of Total Blood Isolates
<i>Escherichia coli</i> , 32% ceftriaxone R	299	19.9%
<i>Enterococcus species</i> , 34% VRE	168	11.2%
<i>Staphylococcus aureus</i> , 31% MRSA	154	10.3%
<i>Klebsiella pneumoniae</i> , 21% ceftriaxone R	142	9.5%
<i>Pseudomonas aeruginosa</i>	56	3.7%
Other Enterobacteriaceae spp.	43	2.9%
<i>Candida glabrata</i>	41	2.7%
<i>Enterobacter cloacae complex</i>	40	2.7%
<i>Proteus mirabilis</i>	39	2.6%
<i>Candida albicans</i>	34	2.3%
<i>Bacteroides species</i>	31	2.1%
<i>Streptococcus anginosus group</i>	29	1.9%
<i>Streptococcus pyogenes</i>	25	1.7%
<i>Klebsiella oxytoca</i>	25	1.7%
<i>Streptococcus pneumoniae</i>	21	1.4%
<i>Stenotrophomonas maltophilia</i>	17	1.1%
<i>Candida tropicalis</i>	16	1.1%
<i>Candida parapsilosis</i>	15	1.0%
<i>Streptococcus agalactiae</i>	14	0.9%

Total blood isolates * 1489

*Excludes

Coagulase-negative *Staphylococcus* (n= 603)

Viridans group *Streptococcus* (n=87)

Corynebacterium spp. (n= 57)

Bacillus spp. (n=25)

Micrococcus spp. (n= 24)

Cutibacterium (Propionibacterium) acnes (n=10)

Aerococcus urinae (n=2)

Table 15. Blood: One Isolate per Patient, 2023 (cont.)

By Organism Group

Gram-positive Bacterial Isolates*			Fungal Isolates		
	n	% of Gram-positive Isolates		n	% of Fungal Isolates
<i>Enterococcus species</i>	168	36%	<i>Candida glabrata</i>	41	29%
<i>Staphylococcus aureus</i>	154	33%	<i>Candida albicans</i>	34	24%
Streptococcus anginosus group	28	6%	<i>Candida tropicalis</i>	16	11%
Streptococcus pyogenes	25	5%	<i>Candida parapsilosis</i>	15	10%
Streptococcus pneumoniae	21	4%	<i>Candida auris</i>	12	8%
<i>Streptococcus agalactiae</i>	14	3%	<i>Candida krusei</i>	5	3%
<i>Staphylococcus lugdunensis</i>	9	2%	<i>Candida guilliermondii</i>	5	3%
Beta Streptococcus group G	8	2%	<i>Candida dubliniensis</i>	4	3%
<i>Granulicatella adiacens</i>	7	1%	<i>Candida species</i>	4	3%
<i>Rothia species</i>	5	1%	<i>Candida lusitanae</i>	1	1%
Total	471		Total	143	


*Excludes other coagulase – negative Staphylococcus, Corynebacterium spp., Bacillus spp., Micrococcus spp.

Gram-negative Bacterial Isolates			Anaerobic Bacterial Isolates*		
	n	% of Gram-negative Isolates		n	% of Anaerobic Bacterial Isolates
<i>Escherichia coli</i>	299	40%	<i>Bacteroides species (includes Parabacteroides)</i>	32	23%
<i>Klebsiella pneumoniae</i>	142	19%	Lactobacillus species	12	9%
Pseudomonas aeruginosa	56	8%	Anaerobic Gram Negative Rod	10	7%
Other Enterobacteriaceae spp.	43	6%	<i>Propionibacterium acnes (Cutibacterium acnes)</i>	10	7%
<i>Enterobacter cloacae complex</i>	40	5%	<i>Fusobacterium nucleatum</i>	8	6%
<i>Proteus mirabilis</i>	39	5%	Lactobacillus sp	6	4%
<i>Klebsiella oxytoca</i>	25	3%	Anaerobic Gram Positive Cocci	6	4%
<i>Stenotrophomonas maltophilia</i>	17	2%	<i>Prevotella species</i>	6	4%
<i>Acinetobacter baumannii complex</i>	9	1%	<i>Eggerthella lenta</i>	4	3%
<i>Citrobacter freundii complex</i>	8	1%	<i>Clostridium perfringens</i>	4	3%
<i>Enterobacter aerogenes (Klebsiella aerogenes)</i>	7	1%	<i>Parvimonas micra</i>	3	2%
<i>Acinetobacter species</i>	7	1%	Anaerobic Gram Positive Rod	3	2%
Salmonella species	7	1%	<i>Gemella haemolysans</i>	3	2%
Haemophilus influenzae	7	1%	<i>Clostridium ramosum</i>	3	2%
			Total	140	

*Excludes Cutibacterium acnes

Mycobacterial Isolates		
	n	% of Mycobacterial Isolates
<i>Mycobacterium avium complex</i>	2	40%
<i>Mycobacterium abscessus</i>	1	20%
<i>Mycobacterium not tuberculosis</i>	1	20%
<i>Mycobacterium mucogenicum</i>	1	20%
Total	5	

Table 16. CSF: One Isolate per Patient, 2023



n = 23

Number of Isolates

Gram-positive bacteria (13)

<i>Staphylococcus hominis</i>	3
<i>Staphylococcus warneri</i>	2
<i>Staphylococcus aureus</i>	2
<i>Bacillus simplex</i>	1
<i>Streptococcus bovis</i> group	1
<i>Corynebacterium</i> species	1
<i>Arcanobacterium haemolyticum</i>	1
<i>Staphylococcus epidermidis</i>	1
<i>Staphylococcus capitis</i>	1

Gram-negative bacteria (3)

<i>Escherichia coli</i>	2
<i>Klebsiella pneumoniae</i>	1

Fungi (4)

<i>Cryptococcus neoformans</i>	2
<i>Naganishia (Cryptococcus) diffluens</i>	1
Mold	1

Anaerobic bacteria (3)

<i>Propionibacterium acnes</i> (<i>Cutibacterium acnes</i>)	2
<i>Clostridium perfringens</i>	1

The following antimicrobial agents are not the drug of choice and may not be effective for treating infections caused by bacteria isolated from CSF:

- Agents administered by oral route only
- First- and second-generation cephalosporins and cephamycins
- Doripenem, ertapenem, and imipenem
- Clindamycin
- Lefamulin
- Macrolides
- Tetracyclines
- Fluoroquinolones

Table 17. Mycobacteria, One Isolate per Patient per Source, 2023

Organisms	No. of Isolates	# Patients By Source ¹		
		Respiratory	Abscess/ wound/ tissue/other	Blood
<i>Mycobacterium avium complex</i>	283	266	15	2
<i>Mycobacterium mucogenicum</i>	130	125	4	1
<i>Mycobacterium abscessus</i>	34	27	6	1
<i>Mycobacterium chelonae</i>	26	21	5	
<i>Mycobacterium gordonae</i>	25	23	2	
<i>Mycobacterium fortuitum group</i>	16	16		
<i>Mycobacterium tuberculosis complex</i>	13	4	9	
<i>Mycobacterium not tuberculosis</i>	8	6	1	1
<i>Mycobacterium kansasii</i>	7	6	1	
<i>Mycobacterium lentiflavum</i>	5	5		
<i>Mycobacterium immunogenum</i>	2	2		
<i>Mycobacterium neoaurum</i>	1	1		
<i>Mycobacterium mageritense</i>	1	1		
<i>Mycobacterium arupense</i>	1	1		
<i>Mycobacterium simiae</i>	1	1		
<i>Mycobacterium xenopi</i>	1	1		
<i>Mycobacterium malmoense</i>	1	1		
<i>Mycobacterium mucogenicum</i>	1	1		
<i>Mycobacterium goodii</i>	1	1		
Total Mycobacteria	557	509	43	5

¹ Some patients have isolates in more than one source.

Table 18. Mycobacteria Antimicrobial Susceptibility Testing

1. *Mycobacterium tuberculosis complex*:

Performed on first isolate per patient; performed on additional isolates recovered after 3 months, testing performed at reference lab.

Primary agents	Secondary agents
Rifampin	Amikacin
Isoniazid (INH)	Capreomycin
Pyrazinamide	Ciprofloxacin
Ethambutol	Ethionamide
	p-aminosalicylic acid
	Streptomycin

2. *Mycobacterium avium complex*:

Performed on first isolate per patient; performed on additional isolates recovered after 3 months, testing performed at reference lab.

Correlation between in vitro susceptibility and clinical response has been demonstrated only for clarithromycin. Clarithromycin results predict azithromycin results. Susceptibility testing for clarithromycin should be performed on isolates from patients only when failing prior macrolide therapy or prophylaxis.

3. Rapidly growing *Mycobacterium* spp. (e.g. *M. abscessus*, *M. chelonae*, and *M. fortuitum* group):

Performed on one isolate per patient, testing performed in-house. Additional agents on request.

Agents routinely reported	Agents conditionally reported
amikacin	imipenem
cefoxitin	linezolid
ciprofloxacin	meropenem
clarithromycin (inducible)	moxifloxacin
doxycycline	tigecycline
trimethoprim-sulfamethoxazole	tobramycin (<i>M. chelonae</i> isolates only)

M. abscessus Clarithromycin and Amikacin drug resistance prediction and subspecies identification by Whole Genome Sequencing is performed by physician request only.

4. Other Nontuberculous Mycobacteria (NTM):

M. kansasii – Performed on one isolate per patient, at reference lab. Other NTM by physician request.

Table 19. California Mycobacterium tuberculosis % Resistant, 2013-2023

Data derived from California Department of Public Health Annual report "California TB Snapshot"¹

Antimicrobial Agent	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Isoniazid	10.6%	9.8%	10.9%	10.9%	7.6% ²	ND	ND	ND	ND	ND	ND
Rifampin	1.8%	1.3%	1.4%	1.8%	0.4% ¹	ND	ND	ND	ND	ND	ND
Ethambutol	1.1%	0.8%	0.7%	ND	ND	ND	ND	ND	ND	ND	ND
Pyrazinamide	6.7%	5.5%	5.1%	5.4%	4.5% ¹	ND	ND	ND	ND	ND	ND
Multi-drug Resistant Tuberculosis rates ³	1.6%	1.1%	1.3%	1.8%	1.8%	1.2%	1.0%	1.0%	0.6%	0.9%	1.1%
MTB Case rate per 100,000 population	5.6	5.5	5.5	5.2	5.2	5.3	5.3	4.3	4.4	4.7	5.4
Number of new cases	2163	2130	2131	2059	2058	2092	2115	1706	1750	1843	2113

¹ <https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/TB-Disease-Data.aspx>

² Excludes multi-drug resistant cases.

³ Multi-drug resistant = Resistant to isoniazid and rifampin.

Table 20. Rapid Grower – Mycobacteria % Susceptible 2022-2023

Organism	No. Isolates	Amikacin ¹	Ciprofloxacin	Clarithromycin	Trimethoprim-sulfamethoxazole
<i>Mycobacterium abscessus</i> complex ^{2, 3, 4, 5}	59	93	R	46	R
<i>Mycobacterium fortuitum</i>	29	99	90	0	97
<i>Mycobacterium chelonae</i>	57	91	—	99	—

¹ Amikacin susceptible breakpoint: Susceptible ≤ 16 µg/mL CLSI M24S 2nd Edition 2023

² *M. abscessus* complex is differentiated into 3 subspecies: *M. abscessus* subsp. *abscessus*, *M. abscessus* subsp. *massiliense* and *M. abscessus* subsp. *bolletii*.

³ Some isolates of *M. abscessus* subsp. *abscessus* and *M. abscessus* subsp. *bolletii* may contain a functional *erm(41)* gene that confers inducible macrolide resistance. Resistance is detected in MIC at day 15, which is routinely tested for.

⁴ *M. abscessus* Clarithromycin and Amikacin drug resistance prediction and subspecies identification by Whole Genome Sequencing is available by physician request.

⁵ Subspecies identification by Whole Genome Sequencing (2020 – 2023) n = 22 *M. abscessus* subsp. *abscessus* = 64%, *M. abscessus* subsp. *massiliense* = 36%, *M. abscessus* subsp. *bolletii* = 0%.

Table 20. Rapid Grower – Mycobacteria % Susceptible 2022-2023

Organism	No. Isolates	Amikacin	Cefoxitin	Ciprofloxacin	Clarithromycin	Doxycycline	Imipenem	Trimethoprim-sulfamethoxazole	Tobramycin
<i>Mycobacterium abscessus</i> complex ^{1, 2, 3, 4}	59	93	36	R	46	R	—	R	—
<i>Mycobacterium fortuitum</i>	29	99	21	90	0	31	—	97	—
<i>Mycobacterium chelonae</i>	57	91	0	7	99	11	—	0	93
<i>Mycobacterium mucogenicum</i>	92	99	99	99	99	89	—	99	—

¹ *M. abscessus* complex is differentiated into 3 subspecies: *M. abscessus* subsp. *abscessus*, *M. abscessus* subsp. *massiliense* and *M. abscessus* subsp. *bolletii*.

² Some isolates of *M. abscessus* subsp. *abscessus* and *M. abscessus* subsp. *bolletii* may contain a functional *erm(41)* gene that confers inducible macrolide resistance. Resistance is detected in MIC at day 15, which is routinely tested for.

³ *M. abscessus* Clarithromycin and Amikacin drug resistance prediction and subspecies identification by Whole Genome Sequencing is available by physician request.

⁴ Subspecies identification by Whole Genome Sequencing (2020 – 2023) n = 22 *M. abscessus* subsp. *abscessus* = 64%, *M. abscessus* subsp. *massiliense* = 36%, *M. abscessus* subsp. *bolletii* = 0%.

Table 21. CLSI Anaerobic Bacteria Cumulative Antibiogram, % Susceptible

Data derived from CLSI M100S 34th edition^{1,2}

<i>Bacteroides</i> spp. and <i>Parabacteroides</i> spp.	Ampicillin–Sulbactam		Piperacillin–Tazobactam		Cefoxitin		Ertapenem		Imipenem		Meropenem		Clindamycin		Moxifloxacin		Metronidazole	
	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S
Breakpoints %S		≤8/4		≤16/4		≤16		≤4		≤4		≤4		≤2		≤2		≤8
<i>Bacteroides fragilis</i>	129	84	1030	96	830	100	133	82	189	97	1505	93	1013	26	256	61	1140	100
<i>Bacteroides thetaiotaomicron</i>	76	82	252	87	258	13	—	—	70	100	328	99	328	28	70	54	322	100
<i>Bacteroides ovatus</i>	30	80	206	94	177	20	19 ²	84 ²	49	100	236	95	207	46	59	41	236	100
<i>Bacteroides vulgatus</i>	20 ³	45	168	92	153	73	—	—	35	97	171	96	171	53	29 ²	31	186	100
<i>Bacteroides uniformis</i>	19 ²	84	78	96	72	85	—	—	19 ²	100	93	100	87	45	25 ²	48	89	100
<i>Parabacteroides distasonis</i>	27 ²	59 ²	92	95	82	29	—	—	26 ²	100	119	97	108	43	37	62	118	100

Other Anaerobic Organisms	Ampicillin–Sulbactam		Piperacillin–Tazobactam		Imipenem		Meropenem		Penicillin		Clindamycin		Moxifloxacin		Metronidazole	
	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S	No. Isolates	%S
Breakpoints %S		≤8/4		≤32/4		≤4		≤4		≤0.5		≤2		≤2		≤8
<i>Prevotella</i> species	29 ²	97 ²	63	100	29	100	92	98	63	100	29 ²	69 ²	92	66	92	99
<i>Fusobacterium</i> species	20 ²	100 ²	55	96	75	95	20 ²	100 ²	—	—	75	77	75	68	75	95
Anaerobic gram-positive cocci ⁴	—	—	1853	99	134	99	1647	100	1647	100	1826	97	300	72	1692	100
<i>Cutibacterium (Propionibacterium) acnes</i>	—	—	18 ²	100 ²	17 ²	94 ²	—	—	—	—	17 ²	53 ²	114	95	18 ²	0 ²
<i>Clostridium perfringens</i>	15 ²	100 ²	410	100	23 ²	100	417	100	402	90	425	83	23 ²	83	425	100
Other <i>Clostridium</i> species	—	—	439	94	71	99	390	100	390	69	461	67	71	62	461	100

¹ CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 34th ed. CLSI Supplement M100. Clinical and Laboratory Standards Institute; 2023.

² Isolates collected from selected US hospitals from January 1st, 2013 to December 31st, 2016.

³ Calculated from fewer than the standard recommendation of 30 isolates.

⁴ Anaerobic gram-positive cocci include *Peptococcus*, *Peptostreptococcus*, *Fingoldia*, *Peptoniphilus*, and *Anaerococcus* species.

Table 22. Antimicrobials (IV,PO) Formulary Status and Cost Reference

Drug	Usual Dose	Usual Interval	(\$)*Per Day
Penicillins			
Ampicillin	1 gm	Q6H	27.60
Ampicillin	2 gm	Q6H	42.10
Ampicillin-sulbactam	3 gm	Q6H	33.55
Oxacillin(24-hr infusion)	12 gm	Q24H	65.65
Penicillin G (24-hr infusion)	24 million units	Q24H	61.40
Piperacillin-tazobactam (Extended 4-hr infusion) RTU ^Δ	4.5 gm	Q8H	36.90
Amoxicillin (PO)	500 mg	Q8H	0.25
Amoxicillin- clavulanic acid (PO)	500 mg	Q8H	1.35
Amoxicillin- clavulanic acid (PO)	875 mg	Q12H	0.45
Cephalosporins			
Cefazolin RTU ^Δ	1 gm	Q8H	10.65
Cefazolin RTU ^Δ	2 gm	Q8H	21.00
Cefepime ^{1,2} RTU ^Δ	1 gm	Q8H	27.85
Cefepime ^{1,2} RTU ^Δ	2 gm	Q8H	43.65
Cefoxitin (peri-operative only) ^{1,3}	2 gm	once	10.40
Ceftriaxone RTU ^Δ	1 gm	Q24H	9.40
Ceftriaxone RTU ^Δ	2 gm	Q24H	18.20
Cephalexin (PO)	500 mg	Q6H	0.70
Cefpodoxime (PO-UTI)	100 mg	Q12H	3.25
Cefpodoxime (PO)	200 mg	Q12H	4.95
Carbapenems/monobactam			
Aztreonam ^{1,4}	2 gm	Q8H	176.15
Ertapenem ^{1,5}	1 gm	Q24H	28.10
Meropenem ^{1,6}	1 gm	Q8H	81.10
Aminoglycosides			
Amikacin ^{1,7}	1000 mg (15 mg/kg/dose)	Q24H	11.30
Gentamicin	500 mg (7 mg/kg/dose)	Q24H	23.80
Tobramycin ^{1,8}	500 mg (7 mg/kg/dose)	Q24H	13.25

Table 22. Antimicrobials (IV,PO) Formulary Status and Cost Reference
(cont.)

Drug	Usual Dose	Usual Interval	(\$)*Per Day
Other Antimicrobials (Intravenous)			
Azithromycin ¹⁰	500 mg	Q24H	7.25
Ciprofloxacin ¹⁰	400 mg	Q12H	5.15
Clindamycin ¹⁰	600 mg	Q8H	13.50
Colistimethate ^{1,9}	150 mg (CBA)**	Q12H	28.50
Daptomycin ^{1,9}	500 mg	Q24H	20.35
Doxycycline ¹⁰	100 mg	Q12H	40.10
Levofloxacin ¹⁰	750 mg	Q24H	2.00
Linezolid ^{1, 10,11}	600 mg	Q12H	14.45
Metronidazole ¹⁰	500 mg	Q8H	4.30
Rifampin ^{1, 10}	600 mg	Q24H	166.35
Tigecycline ^{1,9}	50 mg	Q12H	44.35
TMP/SMX ^{***,10}	320 mg TMP	Q12H	34.20
Vancomycin RTU ^Δ	1 gm	Q12H	17.05
Other Antimicrobials (Oral)			
Azithromycin (PO)	500 mg	Q24H	1.60
Ciprofloxacin (PO)	500 mg	Q12H	0.35
Clarithromycin (PO)	500 mg	Q12H	6.85
Clindamycin (PO)	600 mg	Q8H	0.65
Doxycycline (PO)	100 mg	Q12H	2.20
Levofloxacin (PO)	750 mg	Q24H	0.40
Linezolid (PO) ^{1,11}	600 mg	Q12H	3.35
Metronidazole (PO)	500 mg	Q8H	1.10
Nitrofurantoin (PO) (monohydrate/ macrocrystal formulation)	100 mg	Q12H	4.00
Rifampin (PO)	600 mg	Q24H	1.15
TMP/SMX (PO)	160 mg/800 mg	Q12H	0.30
Vancomycin (PO-cap)	125 mg	Q6H	4.00
Vancomycin (PO-susp)	125 mg	Q6H	10.00

Table 22. Antimicrobials (IV,PO) Formulary Status and Cost Reference
(cont.)

Drug	Usual Dose	Usual Interval	(\$)*Per Day
Antifungal Agents (Intravenous)			
Amphotericin B	50 mg	Q24H	39.75
Amphotericin B ^{1,9} Liposomal (AmBisome)	400 mg	Q24H	751.95
Micafungin ¹	50 mg	Q24H	19.35
Micafungin ¹	100 mg	Q24H	28.15
Fluconazole	400 mg	Q24H	10.60
Isavuconazonium ^{1,9}	372 mg	Q24H	350.95
Posaconazole ^{1,5,10,12}	300 mg	Q24H	248.95
Voriconazole ^{1,10,13}	300 mg	Q12H	60.60
Antifungal Agents (Oral)			
Fluconazole (PO)	400 mg	Q24H	2.20
Isavuconazonium (PO) ^{1,9}	372 mg	Q24H	203.05
Posaconazole (PO-DR) ^{1,5,12}	300 mg	Q24H	58.10
Voriconazole (PO) ^{1,13}	200 mg	Q12H	40.80

△ RTU= "Ready to Use" IV bags

* Includes drug acquisition cost plus estimated preparation and administrative costs; charges rounded up to the nearest \$0.05

** CBA: Colistin-base activity

***TMP/SMX: Trimethoprim/Sulfamethoxazole

¹ Use of Controlled Formulary (CF) antimicrobials is restricted to UCLA Health System-approved criteria.

² Restricted: suspected or documented *Pseudomonas aeruginosa* infection and in the management of gram-negative meningitis.

³ Restricted: surgical prophylaxis; refer to Pre-incisional Antimicrobial Recommendations.

⁴ Restricted: aerobic gram-negative infections in patients with documented IgE-mediated hypersensitivity to beta-lactam antibiotics.

⁵ For Pediatric patients: restricted to use by Pediatric Infectious Diseases Service approval.

⁶ Restricted: clinical deterioration on concurrent/recent antimicrobials or febrile neutropenia and/or overt sepsis in an immunocompromised patient.

⁷ Restricted: organisms with suspected/documentated resistance to gentamicin and tobramycin.

Restricted: infections caused by organisms with suspected/documentated resistance to gentamicin.

Restricted: requires formal consultation by an Infectious Diseases physician; exceptions noted in HS 1444.

Injection: For use in patients unable to tolerate the oral formulations.

Restricted: suspected or documented VRE infection, documented allergy to vancomycin (not Redman's Syndrome).

For prophylaxis of invasive *Aspergillus* and *Candida* infections in severely immunocompromised patients.

⁸ Restricted: treatment of suspected/documentated invasive aspergillosis. For treatment of infections caused by *S. apiospermum*, *Fusarium* species (including *F. solani*) and non-albicans *Candida* species in patients intolerant of, or refractory to other therapy.

Table 23. Indications for Performing Routine Antimicrobial Susceptibility Tests – Aerobic Bacteria

Susceptibility tests will be performed as follows:

1. Blood—all isolates except*:

- Aerococcus* spp.¹ (excludes *Aerococcus urinae*)
- Bacillus* spp.¹
- Corynebacterium* spp.¹ (excludes *Corynebacterium jeikeium* and *Corynebacterium striatum*)
- Coagulase-negative *Staphylococcus*^{1,2}
- Cutibacterium (Propionibacterium) acnes*¹
- Micrococcus* spp.¹
- Viridans group *Streptococcus*¹ (excludes *Streptococcus anginosus* group)

2. Urine

>10⁵ CFU/ml (1 or 2 species)

>50,000 CFU/ml (pure culture):

- Gram-negative bacilli; *Staphylococcus aureus*

Urine from Urology – Susceptibility performed based on the following criteria upon request

Workup for up to 5 organisms;

Any quantity of pathogens

- Gram-negative bacilli
- *Staphylococcus aureus*

Potential pathogens – Colony count of ≥50K for ≤2 organisms

- Coagulase Negative *Staphylococcus*
- Viridans *Streptococcus*
- *Corynebacterium* species
- Yeast
- *Staphylococcus saprophyticus*
- *Aerococcus* species
- Beta hemolytic *Streptococcus*

Enterococcus species

- ≤2 organism any quantity
- Colony count of <50K Predominant in mix culture
- Colony count of ≥50K Non-predominant in mixed culture

3. Respiratory (sputum, nasopharynx, bronchial washing and tracheal aspirate):

Moderate /many growth ≤2 potential pathogens

Cystic fibrosis patients: any quantity of gram-negative bacilli, *S. aureus*, *S. pneumoniae*

4. Stool

Salmonella spp. (≤ 3 mo. only or susceptibilities performed on all isolates of *S. typhi* and *S. paratyphi*)

Shigella spp.

Yersinia spp.

Vibrio spp.

* Neonates (≤3 months), susceptibilities performed on all isolates

¹ Susceptibilities performed if isolated from multiple cultures

² Susceptibilities performed on all isolates of *S. lugdunensis*

Table 23. Indications for Performing Routine Antimicrobial Susceptibility Tests – Aerobic Bacteria
(cont.)

5. Wounds, abscesses and other contaminated body sites, ≤ 2 potential pathogens.
6. If isolate is from sterile body site, susceptibility testing will be performed on subsequent isolates from similar site(s) every 3 days. Exception: *S. aureus* and *P. aeruginosa* tested each day of collection from blood.
7. If isolate is from non-sterile body site, susceptibility testing will be performed on subsequent isolates from similar site(s) every 5 days.

Additional notes:

- Susceptibility tests will not be performed on more than two potential pathogens per culture unless specifically requested following discussion with clinician.
- Blood and CSF isolates are held for 1 year.
- Other potentially significant isolates are held in lab for 7 days. Contact lab at (310) 794-2758 within 48 hours if susceptibilities are desired.

Table 24. Antimicrobial Agents Routinely Reported – Aerobic Bacteria

Primary antimicrobials	Conditions for supplemental antimicrobial reporting	Supplemental antimicrobial(s) ¹
<i>E. coli</i>, <i>Klebsiella</i> spp., <i>P. mirabilis</i> – Excludes urine isolates		
amoxicillin/clavulanate cefazolin ceftriaxone ciprofloxacin (>11 y.o.) gentamicin piperacillin-tazobactam trimethoprim-sulfamethoxazole	Resistant to ceftriaxone Resistant to ertapenem (>18 y.o.) Resistant to gentamicin Resistant to piperacillin-tazobactam	ertapenem (>18 y.o.), imipenem & meropenem (≤18 y.o.) imipenem, meropenem amikacin, tobramycin ertapenem (>18 y.o.), imipenem & meropenem (≤18 y.o.)
<i>E. coli</i>, <i>Klebsiella</i> spp., <i>P. mirabilis</i> – Urine isolates		
ampicillin amoxicillin/clavulanate oral cephalosporins ² ceftriaxone ciprofloxacin (>11 y.o.) gentamicin nitrofurantoin piperacillin-tazobactam trimethoprim-sulfamethoxazole	Resistant to ceftriaxone Resistant to ertapenem (>18 y.o.) Resistant to gentamicin Resistant to piperacillin-tazobactam	ertapenem (>18 y.o.), imipenem & meropenem (≤18 y.o.) imipenem, meropenem tobramycin ertapenem (>18 y.o.), imipenem & meropenem (≤18 y.o.)

¹ The following additional antimicrobial agents are reported on carbapenem resistant Enterobacterales (resistant to meropenem and/or imipenem): azteonom, azithromycin, minocycline, moxifloxacin, tigecycline, ceftazidime-avibactam and ceftolozane-tazobactam.

² Cefazolin results should only be used to predict potential effectiveness of oral cephalosporins for uncomplicated UTIs.

Table 24. Antimicrobial Agents Routinely Reported – Aerobic Bacteria (cont.)

Primary antimicrobials	Conditions for supplemental antimicrobial reporting	Supplemental antimicrobial(s) ³
Other Enterobacterales organisms⁴ – Excludes urine isolates		
amoxicillin/clavulanate cefepime	Resistant to cefepime	ertapenem (>18 y.o.), imipenem & meropenem (≤18 y.o.)
ceftriaxone ciprofloxacin (>11 y.o.) gentamicin piperacillin-tazobactam ⁵	Resistant to ertapenem (>18 y.o.) Not reported for HECK-Y organisms ⁵	imipenem, meropenem
trimethoprim-sulfamethoxazole	Resistant to gentamicin Resistant to piperacillin-tazobactam	amikacin, tobramycin ertapenem (>18 y.o.), imipenem & meropenem (≤18 y.o.)
Other Enterobacterales organisms³ – Urine isolates		
ampicillin amoxicillin/clavulanate cefepime	Resistant to cefepime	ertapenem (>18 y.o.), imipenem & meropenem (≤18 y.o.)
ceftriaxone ciprofloxacin (>11 y.o.) gentamicin nitrofurantoin piperacillin-tazobactam	Resistant to ertapenem (>18 y.o.) Not reported for HECK-Y organisms ⁵	imipenem, meropenem
trimethoprim-sulfamethoxazole	Resistant to gentamicin Resistant to piperacillin-tazobactam	tobramycin ertapenem (>18 y.o.), imipenem & meropenem (≤18 y.o.)

³ The following additional antimicrobial agents are reported on carbapenem resistant Enterobacterales (resistant to meropenem and/or imipenem): azteonam, azithromycin, minocycline, moxifloxacin, tigecycline, ceftazidime-avibactam and ceftolozane-tazobactam.

⁴ *Enterobacterales* other than *E. coli*, *Klebsiella* spp., *P. mirabilis*, *Salmonella* spp., *Shigella* spp.

⁵ Ceftriaxone not reported for *Citrobacter freundii* complex, *Enterobacter cloacae* complex, *Klebsiella aerogenes*, *Hafnia alvei*, *Yersinia enterocolitica*.

Table 24. Antimicrobial Agents Routinely Reported – Aerobic Bacteria (cont.)

Primary antimicrobials	Conditions for supplemental antimicrobial reporting	Supplemental antimicrobial(s) ¹
<i>Salmonella</i> spp.,¹ <i>Shigella</i> spp.²		
ciprofloxacin (>11 y.o.) trimethoprim-sulfamethoxazole	<i>Shigella</i> spp. Non-fecal sources/resistant to all primary antimicrobials	azithromycin ceftriaxone
<i>Pseudomonas aeruginosa</i>		
cefepime	Resistant to cefepime	imipenem, meropenem, ceftolozane - tazobactam
	Resistant to imipenem or meropenem	ceftolozane - tazobactam
ciprofloxacin (>11 y.o.) Tobramycin piperacillin-tazobactam ceftazidime	ceftolozane – tazobactam MIC ≥4 µg/mL Urine Resistant to piperacillin-tazobactam	cefiderocol amikacin imipenem, meropenem
<i>Acinetobacter</i> spp.		
cefepime ceftazidime ciprofloxacin (>11 y.o.)	Resistant to ceftazidime	imipenem, meropenem
gentamicin piperacillin-tazobactam trimethoprim-sulfamethoxazole	Resistant to meropenem or imipenem Resistant to gentamicin	minocycline amikacin, tobramycin
<i>Stenotrophomonas maltophilia</i>- Sterile body site isolates		
<i>Burkholderia cepacia</i> complex		
levofloxacin (>11 y.o.) minocycline trimethoprim-sulfamethoxazole	<i>Burkholderia cepacia</i> complex <i>Burkholderia cepacia</i> complex	meropenem ceftazidime

¹ If stool isolates, perform on patients ≤3 mo., or if isolate is *Salmonella typhi* or *Salmonella paratyphi* A.

² Susceptibility performed on stool isolates.

Table 24. Antimicrobial Agents Routinely Reported – Aerobic Bacteria (cont.)

Primary antimicrobials	Conditions for supplemental antimicrobial reporting	Supplemental antimicrobial(s)
Nonfermenting Gram Negative Rods not otherwise listed		
cefepime		
ceftazidime	Resistant to ceftazidime	imipenem, meropenem
ciprofloxacin (>11 y.o.)		
gentamicin	If gentamicin >1 µg/ml	amikacin, tobramycin
piperacillin-tazobactam		
trimethoprim-sulfamethoxazole		
<i>Haemophilus influenzae</i>		
Beta-lactamase test	Sterile body site isolates:	Reported upon request:
	If beta-lactamase positive	ceftriaxone
	If beta-lactamase negative	ampicillin, ceftriaxone
	CSF only	Meropenem

Table 24. Antimicrobial Agents Routinely Reported – Aerobic Bacteria (cont.)

Primary antimicrobials	Conditions for supplemental antimicrobial reporting	Supplemental antimicrobial(s)
<i>Staphylococcus spp.</i>		
clindamycin ¹		
oxacillin	<i>S. aureus</i> (exclude Blood and CSF) Resistant to oxacillin (MRSA)	tetracycline/doxycycline, trimethoprim-sulfamethoxazole All beta-lactams considered resistant except ceftaroline
penicillin		
vancomycin	<i>S. aureus</i> on blood (vancomycin $\geq 2\mu\text{g/ml}$)	daptomycin, linezolid
	Urine isolates	ciprofloxacin ² , nitrofurantoin, trimethoprim-sulfamethoxazole
<i>Enterococcus spp.</i>		
ampicillin		
vancomycin	Resistant to vancomycin (VRE) from sterile body sites	daptomycin, doxycycline, linezolid, quinupristin-dalfopristin (excluding <i>E. faecalis</i>), rifampin
	Sterile body site isolates	gentamicin (high level)
	Urine isolates	ciprofloxacin ² , doxycycline, nitrofurantoin
<i>Streptococcus pneumoniae</i>		
amoxicillin, cefotaxime, ceftriaxone, erythromycin ³ , levofloxacin ² , penicillin, tetracycline ³ , trimethoprim-sulfamethoxazole ³ , vancomycin		
Viridans group <i>Streptococcus</i>		
cefotaxime, ceftriaxone, penicillin, vancomycin		
Beta-hemolytic <i>Streptococcus</i>		
Clindamycin ¹ , penicillin, vancomycin		
<i>Listeria monocytogenes</i>		
penicillin, trimethoprim-sulfamethoxazole (penicillin results predicts ampicillin results)		

¹ Excluding urine and CSF isolates

² Patients >11 y.o.

³ Excluding CSF isolates

Table 25: CLSI M62 – Expected Antimicrobial Susceptibility Patterns of the Most Commonly Isolated Nocardia Data Derived from CLSI M62†

Organism	Amoxicillin/ clavulanic acid	Ceftriaxone	Imipenem	Ciprofloxacin	Minocycline	Linezolid	Trimethoprim – sulfamethoxazole	Amikacin	Tobramycin	Clarithromycin
<i>N. abscessus</i>	S	S	V	R	V	S	S	S	V	R
<i>N. brasiliensis</i>	S	V	R	R	V	S	S	S	S	R
<i>N. cyriacigeorgica</i>	R	S	V	R	V	S	S	S	S	R
<i>N. farcinica</i>	S	R	V	V	V	S	S	S	R	R
<i>N. nova complex*</i>	R	V	S	R	V	S	S	S	R	S
<i>N. otitiscaviarum</i>	R	R	R	V	V	S	S	S	S	V
<i>N. pseudobrasiliensis</i>	R	R	R	S	R	S	V	S	S	S
<i>N. transvalensis complex**</i>	V	S	V	S	V	S	S	R	R	R

† Adapted from CLSI M62 2nd edition, February 2023

* *N. nova complex* includes *N. africana*, *N. elegans*, *N. kruczakiae*, *N. nova*, and *N. veterana*

** *N. transvalensis complex* include *N. blacklockiae*, *N. transvalnesis*, and *N. wallacei*

Table 26. Susceptible MIC ($\mu\text{g/mL}$) Breakpoints for Aerobic Gram-negative Bacilli †

	Penicillins			Cephalosporins					Carbapenems			Amino-glycosides			Fluoro-quinolones		Other								
	Ampicillin	Ampicillin-sulbactam	Piperacillin-tazobactam	Cefazolin	Cefepime	Cefotaxime	Ceftazidime	Ceftriaxone	Ertapenem	Imipenem	Meropenem	Amikacin	Gentamicin	Tobramycin	Ciprofloxacin ¹	Levofloxacin ²	Colistin ³	Trimethoprim – sulfamethoxazole	Nitrofurantoin	Minocycline	Tigecycline	Ceftolozane-tazobactam	Ceftazidime-avibactam	Meropenem-vaborbactam	
<i>Enterobacterales</i>	≤8	≤8	≤8	≤2	≤2	≤1	≤4	≤1	≤0.5	≤1	≤1	≤4	≤2	≤2	≤0.25	≤0.5	≤2	≤2/38	≤32	≤4	≤2	≤2/4	≤8/4	≤4/8	
NONFERMENTERS																									
<i>Acinetobacter species</i>	R	≤8	≤16	R	≤8	≤8	≤8	≤8	R	≤2	≤2	≤16	≤4	≤4	≤1	≤2	≤2	≤2/38	–	≤4	–	–	–	–	
<i>Burkholderia cepacia complex</i>	R	R	R	R	R	–	≤8	R	R	R	≤4	R	R	R	–	≤2	R	≤2/38	–	≤4	–	–	–	–	
<i>Pseudomonas aeruginosa</i>	R	R	≤16	R	≤8	R	≤8	R	R	≤2	≤2	≤16 ⁴	–	≤1	≤0.5	≤1	≤2	R	–	–	R	≤4/4	≤8/4	–	
<i>Stenotrophomonas maltophilia</i>	R	R	R	R	–	R	–	R	R	R	R	R	R	R	–	≤2	–	≤2/38	–	≤1	–	–	–	–	
Other non-fermenters	–	–	≤16	–	≤8	≤8	≤8	≤8	–	≤4	≤4	≤16	≤4	≤4	≤1	≤2	–	≤2/38	–	≤4	–	–	–	–	

† Data derived from CLSI M100 34th edition.

¹ *Salmonella* spp. breakpoint for ciprofloxacin ≤ 0.06 $\mu\text{g/ml}$

² *Salmonella* spp. breakpoint for levofloxacin ≤ 0.12 $\mu\text{g/ml}$

³ There are no susceptible category for colistin. The MIC is based on the new CLSI Intermediate breakpoint at for Colistin at ≤ 2 $\mu\text{g/mL}$

⁴ Amikacin breakpoints for *Pseudomonas aeruginosa* for Urine sources only.

Table 27. Susceptible MIC ($\mu\text{g/mL}$) Breakpoints for Aerobic Gram-positive Cocci†

Organism	Penicillins			Cephalo- sporin	Aminogly- cosides		Fluoro- quinolone	Other									
	Ampicillin	Oxacillin	Penicillin	Ceftaroline ¹	Gentamicin	Gentamicin synergy	Ciprofloxacin	Clindamycin	Daptomycin	Doxycycline	Erythromycin	Linezolid	Nitrofurantoin	Quinupristin- dalbapristin	Rifampin	Trimethoprim – sulfamethoxazole	Vancomycin
<i>Staphylococcus aureus</i> <i>Staphylococcus lugdunensis</i>	≤ 1	≤ 2	$\leq 0.12^2$	≤ 1	≤ 4	–	≤ 1	≤ 0.5	≤ 1	≤ 4	≤ 0.5	≤ 4	≤ 32	≤ 1	≤ 1	$\leq 2/38$	$\leq 2^1$
Coagulase-negative <i>Staphylococcus</i>	–	≤ 0.5	$\leq 0.12^2$	–	≤ 4	–	≤ 1	≤ 0.5	≤ 1	≤ 4	≤ 0.5	≤ 4	≤ 32	≤ 1	≤ 1	$\leq 2/38$	≤ 4
<i>Enterococcus</i> spp. <i>Enterococcus faecalis</i>	≤ 8	–	≤ 8	R	R	≤ 500	≤ 1	R	≤ 2	≤ 4	R	≤ 2	≤ 32	≤ 1	≤ 1	R	≤ 4
<i>Enterococcus faecium</i>	≤ 8	–	≤ 8	R	R	≤ 500	≤ 1	R	≤ 4	≤ 4	R	≤ 2	≤ 32	≤ 1	≤ 1	R	≤ 4

Organism	Penicillins		Cephalosporins		Tetracyclines		Other		
	Amoxicillin	Penicillin	Cefotaxime	Ceftriaxone	Doxycycline	Tetracycline	Erythromycin	Levofloxacin	Vancomycin
<i>Streptococcus pneumoniae</i>	–	–	–	–	≤ 0.25	≤ 1	–	≤ 2	≤ 1
Meningitis	–	≤ 0.06	≤ 0.5	≤ 0.5	–	–	–	–	–
Non-meningitis	≤ 2	≤ 2	≤ 1	≤ 1	–	–	≤ 0.25	–	–
Viridans group <i>Streptococcus</i>	–	≤ 0.12	≤ 1	≤ 1	–	–	–	–	≤ 1

† Data derived from CLSI M100 34th edition.

1 *S. aureus* only, including MRSA

2 beta-lactamase negative

Table 28. Antimicrobial Stewardship

- 1) Treatment of asymptomatic bacteriuria
 - a. A urine culture must ALWAYS be interpreted in the context of the urinalysis and patient symptoms.
 - b. If a patient has no signs of infection on urinalysis and no symptoms of infection, but a positive urine culture, the patient by definition has **asymptomatic bacteriuria**.
 - c. Patients with chronic indwelling catheters, urinary stoma, and neobladders will almost universally have positive urine cultures.
 - d. The only patient populations for which it is recommended to screen for and treat asymptomatic bacteriuria are **pregnant women** and **patients scheduled for a genitourinary surgical procedure**. Screening during the first 2 months of renal transplant is acceptable.
 - e. Avoid routine urine analysis and/or urine cultures for the sole purpose of screening for UTI in asymptomatic patients.
- 2) Treatment of VRE Isolated from stool cultures
 - a. *Enterococcus* are normal bowel flora and do not cause enteric infections, regardless of vancomycin susceptibility.
 - b. Antibiotic treatment of VRE in stool cultures is discouraged, and may lead to increased transmission by causing diarrhea and emergence of antimicrobial resistance among VRE.
- 3) Treatment of *Candida* isolated from bronchoscopic samples in non-neutropenic patients
 - a. Isolation of *Candida*, even in high concentrations, from respiratory samples of immunocompetent patients, including bronchoscopy, should be interpreted as airway colonization.
 - b. Antifungal therapy should not be initiated unless *Candida* is also isolated from sterile specimens or by histologic evidence in tissue from at-risk patients.
- 4) Use of “double coverage” for gram-negative bacteria
 - a. “Double coverage” of suspected gram-negative infections serves the purpose of providing broad spectrum initial empiric coverage until susceptibility data are known.
 - b. No evidence exists to support the superiority of combination therapy over monotherapy for gram-negative infections once susceptibilities are known.
 - c. Once culture identification and susceptibilities have been reported, de-escalation to a single agent is strongly recommended.
- 5) Use of two agents with anaerobic activity to treat infections with potential anaerobic bacteria involvement
 - a. Double anaerobic coverage is not necessary and puts the patient at risk for additional drug toxicities. No data or guidelines support double anaerobic coverage in clinical practice.
 - b. Example: use of piperacillin/tazobactam + metronidazole.
 - c. Two clinical exceptions are:
 - i. Addition of metronidazole to another agent with anaerobic activity to treat *Clostridioides difficile* infection.
 - ii. Clindamycin added to another agent with anaerobic activity when treating necrotizing fasciitis.

For additional information, refer to the Antimicrobial Stewardship website, <https://asp.mednet.ucla.edu/pages/>